Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma

Citation
Sg. Urba et al., Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma, J CL ONCOL, 19(2), 2001, pp. 305-313
Citations number
21
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0732183X → ACNP
Volume
19
Issue
2
Year of publication
2001
Pages
305 - 313
Database
ISI
SICI code
0732-183X(20010115)19:2<305:RTOPCV>2.0.ZU;2-P
Abstract
Purpose: A pilot study of 43 patients with potentially resectable esophagea l carcinoma treated with an intensive regimen of preoperative chemoradiatio n with cisplatin, fluorouracil, and vinblastine before surgery showed a med ian survival of 29 months in comparison with the la-month median survival o f 100 historical controls treated with surgery alone at the same institutio n. We designed a randomized trial to compare survival for patients treated with this preoperative chemoradiation regimen versus surgery alone. Materials and Methods: One hundred patients with esophageal carcinoma were randomized to receive either surgery alone (arm I) or preoperative chemorad iation (arm II) with cisplatin 20 mg/m(2)/d on days 1 through 5 and 17 thro ugh 21, fluorouracil 300 mg/ m(2)/d on days 1 through 21, and vinblastine 1 mg/ m(2)/d on days 1 through 4 and 17 through 20. Radiotherapy consisted o f 1.5-Gy fractions twice daily, Monday through Friday over 21 days, to a to tal dose of 45 Gy. Transhiatal esophagectomy with a cervical esophagogastri c anastomosis was performed on approximately day 42. Results: At median follow-vp of 8.2 years, there is no significant differen ce in survival between the treatment arms. Median survival is 17.6 months i n arm I and 16.9 months in arm II. Survival at 3 years was 16% in arm I and 30% in arm II (P =.15), This study was statistically powered to detect a r elatively large increase in median survival from 1 year to 2.2 years, with at least 80% power. Conclusion: This randomized trial of preoperative chemoradiation versus sur gery alone for patients with potentially resectable esophageal carcinoma di d not demonstrate a statistically significant survival difference. J Clin O ncol 19:305-313. (C) 2001 by American Society of Clinical Oncology.